Definitely agree. Ari price has been pressured downwards. todays...

First 2 Last

Share
Profile

Follow
wishful thinker

116 Posts.

21/07/14

13:50

Post #: 13690220
Share

Originally posted by GreenTint ↑

For the full year FY14...

FMG sold at 86% of the 62% price
ARI sold at 90.5% of the 62% price

So ARI gets about 5% more per tonne.

ARI cash costs are AUD$48
FMG cash costs are US$34 or AUD$37 (audusd 0.92)

So ARI's cash costs are $11 /t more.

Using say Iron Ore (62%) at AU$103, 5% is $5

So FMG is ($11- $5) = $6 / t more profitable

BUT Arrium generates cash from Mining consumables

say EBITDA $170m less SIB capex ($35) = $135m

You could divide $135m / 12.5 (production) = $11 /t

and then deduct this from ARI's Iron ore costs.

So ARI and FMG have the same cost base in effect! +/- a few dollars

Which business has lower gearing? ARI

Which business has a lower interest rate?
ARI 5% compared to FMG 7.5%
* there is a reason for that.

Is ARI trading to reflect this compared to FMG?

No, ARI should be much higher!

OR FMG much lower.

This all assumes Steel is cash flow break even after SIB capex (50% of DA) going forward

The writer implies no investment recommendation.
This report contains material speculative in nature. Investors should seek professional investment advice. The writer owns shares in Arrium.

Expand

Definitely agree. Ari price has been pressured downwards.

todays production report is good in terms what the company is doing. Price is a macro factor. Share priced Shudve bounced a bit but it didn't.

ARI Price at posting: 75.5¢ Sentiment: Hold Disclosure: Held
1 Upvote

0 Great analysis

Reply

Top Stories

AW1

American West does it again at Storm with visually identified thick copper hits at Cyclone, Lightning Ridge

I88

Infini soars 50% as company reveals it could’ve just made uranium history – redefining what it means to be “high grade”

LGM

Legacy shares jump on discovery of multiple epithermal veins at Bauloora JV

GRE

Greentech finds lithium trend across 5.5 km at WA's Kobe South

PYC

PYC commences new study on drug for eye condition Retinitis Pigmentosa type 11